DGAP-News: WILEX AG: Phase III ARISER data for the adjuvant treatment of clear cell renal cancer with RENCAREX(R) including retrospective subgroup analysis presented at ASCO
(firmenpresse) - DGAP-News: WILEX AG / Key word(s): Research Update
WILEX AG: Phase III ARISER data for the adjuvant treatment of clear
cell renal cancer with RENCAREX(R) including retrospective subgroup
analysis presented at ASCO
03.06.2013 / 17:35
---------------------------------------------------------------------
PRESS RELEASE
Phase III ARISER data for the adjuvant treatment of clear cell renal cancer
with RENCAREX(R) including retrospective subgroup analysis presented at
ASCO
- RENCAREX(R) improves disease free survival significantly by over 22
months (44%) in the subgroup of patients (ITT) with a high CAIX score>=2.6 (HR=0.54; p=0.02)
- In patients under the age of 65 years RENCAREX(R) clinically and
statistically improves disease free survival with a CAIX score>= 2.0
(HR=0.60; p=0.01)
Munich, Germany, 03 June 2013 - WILEX AG (ISIN DE0006614720 / WL6 / FSE)
published the results from the Phase III ARISER trial with RENCAREX(R) for
the adjuvant treatment of patients with clear cell renal cell carcinoma at
the Annual Meeting of the American Society of Clinical Oncology (ASCO). The
data were presented by Professor Arie S. Belldegrun, Principal Investigator
of the ARISER trial, Director of the UCLA Institute of Urologic Oncology
and Chief of Urologic Oncology at the David Geffen School of Medicine at
UCLA, Los Angeles.
In the ARISER trial 864 subjects were enrolled from 142 sites across
Europe, North and South America. Baseline demographics were well balanced
across treatment groups. Up to six months of treatment demonstrated an
excellent safety profile and was well tolerated. As reported previously,
the primary endpoint in the ARISER trial was not reached. After 54 months
median duration of follow up, the median disease free survival (DFS) was
71.4 months in the RENCAREX(R) arm and was not reached in the placebo arm
(HR=0.97; p=0.74).
Analysis of the data confirmed that CAIX expression is a characteristic of
ccRCC. However, the antigen density, as determined by the CAIX score,
varies from patient to patient. Subgroup analysis for all CAIX scores from
0.0 to 3.0 revealed that as the CAIX score increases, the more pronounced
the RENCAREX(R) treatment effect becomes. A CAIX score of>= 2.6 resulted
in
a clinically and statistically significant treatment effect with median DFS
increasing from 51.2 months in the placebo arm to 73.6 months in
RENCAREX(R) patients (N=151; HR=0.54; p=0.02).
Patients who had received at least eight consecutive administrations of
study medication (week 1 to 8) and had no major protocol deviation were
defined as the per protocol population. In these patients with a CAIX score>= 2.6 both the hazard ratio and the significance level (N=139; HR=0.51;
p=0.007) improved even further.
In patients under the age of 65 years RENCAREX(R) showed a clinically and
statistically significant DFS with a CAIX score>= 2.0 (N=286; HR=0.60;
p=0.01).
Treatment with RENCAREX(R) has an excellent safety profile and is well
tolerated. The retrospective subgroup analysis indicates that RENCAREX(R)
significantly improves DFS in patients with a high CAIX score i.e. a high
antigen density. The treatment effect could be detected within 24 months of
the start of treatment. Thus the CAIX score may be helpful in identifying
and stratifying patients who may benefit from RENCAREX(R) adjuvant therapy.
RENCAREX(R) could deliver an effective therapy for patients with ccRCC and
a high CAIX score.
Professor Arie Belldegrun commented: 'The ARISER trial, which is one of the
most important prospective trials in kidney cancer in the past decade, has
demonstrated a surprisingly long Disease Free Survival. This might pose a
challenge for adjuvant ccRCC drug development without appropriate patient
stratification. The finding that a subgroup of patients had a 40% lower
risk of recurrence if treated with RENCAREX(R) is important and should be
confirmed in a future prospective trial now that we know that CAIX density
can serve as a predictive companion diagnostic for RENCAREX(R).'
WILEX plans to start discussions with regulatory authorities (FDA and
European Authorities) in the second half of 2013 on a confirmatory
prospective Phase III trial with RENCAREX(R) in the adjuvant therapy of
ccRCC in the defined subgroup using the biomarker CAIX for stratification.
The definition of the subgroup might lead to a revised peak sales potential
of RENCAREX(R) in the adjuvant setting of ccRCC of over 300 million USD.
The stratification by the biomarker CAIX may also be applicable to other
indications with CAIX expression such as colon, non-small cell lung, head
and neck and oesophageal cancer.
Following the recommendation of the IDMC to terminate the ARISER study,
WILEX and its partner Prometheus are currently in discussion on the
formalities and timing regarding the termination of the existing licensing
agreement for the US marketing rights of RENCAREX(R). Once completed, WILEX
will be able to offer a new partner world-wide rights (excluding southern
Europe).
Invitation to the conference call to present the ARISER subgroup data
WILEX will hold a public conference call for media, analysts and investors
on 4 June 2013 at 3:00 p.m. CET in English. Please dial in ten minutes
before the conference call using the following dial-in numbers:
1. Germany: +49 69 71044 5598
2. UK: +44 20 3003 2666
3. USA: +1 212 999 6659
4. USA Freephone: +1 866 966 5335
You will be welcomed by an operator taking your name and company. The
presentation slides for the conference will be available for download at
www.wilex.de on 04 June 2013 at 2:30 p.m. CET.
About RENCAREX(R) and the ARISER study
The drug candidate RENCAREX(R) is based on the antibody Girentuximab, which
binds to the tumour-specific antigen CAIX - an antigen that is
overexpressed in clear cell renal cell carcinomas (ccRCC).
ARISER (Adjuvant RENCAREX(R) Immunotherapy trial to Study Efficacy in
non-metastasised Renal cell carcinoma) was an international, multicentre,
randomised Phase III trial that examined the efficacy of the antibody
RENCAREX(R) in comparison to placebo in the treatment of clear cell renal
cell cancer patients following complete or partial surgical removal of the
affected kidney in patients with no detectable metastases but at high risk
of recurrence. The study enrolled 864 patients that had had prior
nephrectomy of primary RCC no later than 12 weeks before study entry with
documented clear cell histology, an ECOG score of 0 or 1 and no evidence of
macroscopic or microscopic residual disease. Under the treatment schedule
patients received a once-weekly infusion of RENCAREX(R) or placebo (50:50)
for 24 weeks. Patients receiving RENCAREX(R) were dosed at 50 mg in the
first week followed by weekly doses of 20 mg during weeks 2-24.
RENCAREX(R) has Fast Track designation for ccRCC in the USA and Orphan Drug
designation for RCC in the USA and EU.
About WILEX
WILEX AG is a biopharmaceutical company based in Munich, Germany. Focused
on oncology, the Company develops diagnostic and therapeutic product
candidates for the specific detection and targeted treatment of various
types of cancer. In the field of therapeutics, WILEX develops small
molecules (MESUPRON(R) two Phase IIa trials completed, WX-554 in Phase
Ib/II and WX-037 in preclinical development). In the field of diagnostics,
REDECTANE(R) is an antibody-based imaging in vivo diagnostic agent that is
currently in a Phase III programme. The Company also has a portfolio of
research use only tests and in vitro diagnostic agents that are marketed
via its US subsidiary WILEX Inc. in Cambridge, MA, under the brand Oncogene
Science. WILEX's subsidiary Heidelberg Pharma GmbH offers preclinical
contract research services and a highly promising antibody drug conjugate
(ADC) technology platform. The business model of WILEX comprises research
and product development as well as the commercialisation of its activities.
WILEX's customers and partners include leading international pharmaceutical
companies. Website: http://www.WILEX.com, ISIN DE0006614720 / WKN 661472 /
Symbol WL6.
Contact
Katja Arnold (CIRO)
Corporate Communications
WILEX AG
Grillparzerstr. 10
81675 Munich, Germany
Tel.: +49 (0)89-41 31 38-126
Fax: +49 (0)89-41 31 38-99
Email: investors(at)wilex.com
This communication contains certain forward-looking statements relating to
the Company's business, which can be identified by the use of
forward-looking terminology such as 'estimates', 'believes', 'expects',
'may', 'will', 'should', 'future', 'potential' or similar expressions or by
a general discussion of the Company's strategy, plans or intentions. Such
forward-looking statements involve known and unknown risks, uncertainties
and other factors, which may cause our actual results of operations,
financial position, earnings, achievements, or industry results, to be
materially different from any future results, earnings or achievements
expressed or implied by such forward-looking statements. Given these
uncertainties, prospective investors and partners are cautioned not to
place undue reliance on such forward-looking statements. We disclaim any
obligation to update any such forward- looking statements to reflect future
events or developments.
End of Corporate News
---------------------------------------------------------------------
03.06.2013 Dissemination of a Corporate News, transmitted by DGAP - a
company of EquityStory AG.
The issuer is solely responsible for the content of this announcement.
DGAP's Distribution Services include Regulatory Announcements,
Financial/Corporate News and Press Releases.
Media archive at www.dgap-medientreff.de and www.dgap.de
---------------------------------------------------------------------
Language: English
Company: WILEX AG
Grillparzerstr. 10
81675 München
Germany
Phone: +49 (0)89 41 31 38 - 0
Fax: +49 (0)89 41 31 38 - 99
E-mail: info(at)wilex.com
Internet: www.wilex.com
ISIN: DE0006614720
WKN: 661472
Listed: Regulierter Markt in Frankfurt (Prime Standard);
Freiverkehr in Berlin, Düsseldorf, München, Stuttgart
End of News DGAP News-Service
---------------------------------------------------------------------
214538 03.06.2013
Themen in dieser Pressemitteilung:
Unternehmensinformation / Kurzprofil:
Datum: 03.06.2013 - 17:35 Uhr
Sprache: Deutsch
News-ID 265812
Anzahl Zeichen: 13574
contact information:
Kategorie:
Business News
Diese Pressemitteilung wurde bisher 335 mal aufgerufen.
Die Pressemitteilung mit dem Titel:
"DGAP-News: WILEX AG: Phase III ARISER data for the adjuvant treatment of clear cell renal cancer with RENCAREX(R) including retrospective subgroup analysis presented at ASCO"
steht unter der journalistisch-redaktionellen Verantwortung von
WILEX AG (Nachricht senden)
Beachten Sie bitte die weiteren Informationen zum Haftungsauschluß (gemäß TMG - TeleMedianGesetz) und dem Datenschutz (gemäß der DSGVO).
